Vical gets $1.25 million from Navy for swine flu
Vical receives $1.25 million contract from Navy for development of swine flu vaccine
- On 7:25 am EDT, Thursday October 1, 2009
SAN DIEGO (AP) -- Biotechnology company Vical Inc., which has already signed a pact with the U.S. Navy to develop a swine flu vaccine, said Thursday it received a $1.25 million contract to support vaccine production.
The funding from the Navy will go to a Phase 1 clinical trial for a potential vaccine.
In September, the company said its developing swine flu vaccine prompted "robust" immune responses in 100 percent of animals infected with distinct strains of the virus.
The Phase I clinical trial will involve human subjects.
Shares of Vical rose 22 cents, or 5.1 percent, to $4.48 in premarket activity.
Related Headlines
- Vical Completes Final Patient Follow-Up in TransVax(TM) CMV Vaccine Phase 2 Trial - GlobeNewswire
- Big Pullback for Top Swine Flu Small-Caps - Indie Research
- Movers roundup: AeroVironment, Ciena - AP
- Vical will be added to biotech index, shares rise - AP
- Vical Added to NASDAQ Biotechnology Index - GlobeNewswire
Related Blog Headlines
- Three Core Biotech Holdings: Isis, Ligand and Vical - at Seeking Alpha
- CDC Sticking with 'Tried and True' Methods for Flu Vaccines - at Seeking Alpha
- Swine Flu Stocks: Where Are They Now? - at Seeking Alpha
Sponsored Links
-
Trade Stocks? Try Currency Trading
Trade in a highly trending market 24-hrs a day, 5.5 days a week. GFT. -
Earn From 1.90% to 2.20% Apply Online
With GE Capital Corporation. Not An Offer Of Securities For Sale.
-
Buy Stocks for $4
No account or investment minimums. No inactivity fees. Start Today. -
Super Cheap Car Insurance
Get Discount Car Insurance Quotes Online – Rates from $15 / Month.
Tech Ticker Recent Posts
Add Alert Copyright © 2009 The Associated Press. All rights reserved. The information contained in the AP News report may not be published, broadcast, rewritten, or redistributed without the prior written authority of The Associated Press.